Special Section: Autologous Stem Cell Transplantations in Solid Tumours: Autologous Stem Cell Transplantation in Breast Cancer

References

• Overgaard M, Christensen Juul J, Joansen H, et al. Evaluation of radiotherapy in high-risk breast cancer patients: report from the Danish Breast Cancer Cooperative Group (DBCG 82) trial. Int J Radiat Oncol Biol Ptys 1990; 19: 1121–4
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992; 339: 71–85; 1–15
   PubMed Web of Science ®Google Scholar
• Eddy D M. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer. J Clin Oncol 1992; 10: 657–70
   PubMed Web of Science ®Google Scholar
• Myers S E, Williams S F. Role of high-dose chemotherapy and autologous stem cell support in treatment of breast cancer. Hematol Oncol Clin North Am 1993; 7: 631–45
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node positive breast cancer. The results of 20 years of follow-up. N Engl J Med 1995; 332: 901–6
   PubMed Web of Science ®Google Scholar
• Mouridsen H T. Systemic therapy of advancer breast cancer. Drugs 1992; 44: 17–28, Suppl 4
   PubMedGoogle Scholar
• Carmo-Pereira J, Oliveira Costa F, Henriques E, et al. A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma. Br J Cancer 1987; 56: 471–3
   PubMed Web of Science ®Google Scholar
• Hortobagyi G N, Bodey G R, Buzdar A U, et al. Evaluation of high-dose vs. standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. J Clin Oncol 1987; 5: 354–64
   PubMed Web of Science ®Google Scholar
• French Epirubicin Study. A prospective randomized phase II trial comparing combination chemotherapy with cyclophosphamide, fluorouracil and either doxorubicin or epirubicin. J Clin Oncol 1988; 4: 679–88
   Google Scholar
• Wood W C, Budman D R, Korzun A H, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994; 330: 1253–9
   PubMed Web of Science ®Google Scholar
• Nemoto T, Vana J, Bedwani R N, Baker H W, Mc Gregor F H, Murphy G R. Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer 1980; 45: 2917–24
   PubMed Web of Science ®Google Scholar
• Buzdar A U, Kau S W, Smith T L, Hortobagyi G N. Ten-year results of FAC adjuvant chemotherapy trial in breast cancer. Am J Clin Oncol 1989; 12: 123–8
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Rossi A, Valagussa P, et al. Adjuvant CMF chemotherapy in operable breast cancer: 10 years later. World J Surg 1985; 9: 707–13
   PubMed Web of Science ®Google Scholar
• Ung O, Langlands A O, Barraclough B, Boyages J. Combined chemotherapy and radiotherapy for patients with beast cancer and extensive nodal involvement. J Clin Oncol 1995; 13: 435–43
   PubMed Web of Science ®Google Scholar
• Bearman S I, Overmoyer B A, Bolwell B G, et al. High-dose chemotherapy with autologous peripheral blood progenitor cells for stage II/III breast cancer in patients with 4–9 involved axillary lymph nodes. Proc Am Soc Clin Oncol 1995; 14: 133
   Google Scholar
• Peters W P, Ross M, Vredenburgh J J, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132–43
   PubMed Web of Science ®Google Scholar
• Peters W P, Berry D, Vredenburgh J J, et al. Five-year follow-up of high-dose combination alkylating agents with ABMT as consolidation after standard-dose CAF for primary breast cancer involving 10 axillary lymph nodes. Proc Am Soc Clin Oncol 1995; 14: 317
   Google Scholar
• Dunphy F R, Spitzer G, Buzdar A U, et al. Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol 1990; 8: 1207–16
   PubMed Web of Science ®Google Scholar
• Eder J P, Antman K, Peters W, et al. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol 1986; 4: 1592–7
   PubMed Web of Science ®Google Scholar
• Fields K K, Perkins J P, Hiemenz J W, et al. Intensive ifosfamide, carboplatin, and etoposide followed by autologous stem cell rescue: results of a phase I/II study in breast cancer. Surg Oncol 1993; 2: 87–95
   PubMed Web of Science ®Google Scholar
• Kennedy M J, Beveridge R A, Rowley S D, Godon G B, Abeloff M D, Davidson N E. High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst 1991; 83: 920–6
   PubMed Web of Science ®Google Scholar
• Peters W P, Shpall E J, Jones R B, et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 1988; 6: 1368–76
   PubMed Web of Science ®Google Scholar
• Wallerstein R, Jr, Spitzer G, Dunphy F, et al. A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer. J Clin Oncol 1990; 8: 1782–8
   PubMed Web of Science ®Google Scholar
• Bezwoda W R, Seymour L, Dansey R D. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995; 13: 2483–9
   PubMed Web of Science ®Google Scholar
• Kennedy M J. High-dose chemotherapy of breast cancer: is the question answered? (Editorial). J Clin Oncol 1995; 13: 2477–9
   PubMed Web of Science ®Google Scholar
• Ayash L J. High dose chemotherapy with autologous stem cell support for the treatment of metastatic breast cancer. Cancer 1994; 74: 532–5
   PubMed Web of Science ®Google Scholar
• Peters W, Shpall E, Jones R, et al. High-dose combination cycloposphamide, cisplatin, and carmustine with bone marrow support as initial treatment for metastatic breast cancer: 3–6 year follow-up. Proc Am Soc Clin Oncol 1990; 9: 10
   Google Scholar
• Saez R A, Slease R B, Selby G B, Strnad C, Ebstein R B, Confer D L. Long-term survival after autologous bone marrow transplantation for metastatic carcinoma. South Med J 1995; 88: 320–6
   PubMed Web of Science ®Google Scholar
• Hortobagyi G N. High-dose chemotherapy is not an established treatment for breast cancer. Proc Am Soc Clin Oncol 1995; 341–6, Suppl
   Web of Science ®Google Scholar
• Rahman Z, Frye D, Buzdar A, Hortobagyi G. A retrospective analysis to evaluate the impact of selection process for high-dose chemotherapy on the outcome of patients with metastatic breast cancer. Proc Am Soc Clin Oncol 1995; 14: 95
   Google Scholar
• Crews J R, Vredenburgh J, Bigner S, et al. Incidence of myelodysplastic syndrome and acute myeloid leukemia after high-dose chemotherapy and autologous bone marrow transplant. Proc Am Soc Clin Oncol 1995; 14: 317
   Google Scholar
• Cagnoni P J, Stemmer S M, Matthes S, et al. Phase I trial of high dose paclitaxel (Taxol), cyclophosphamide and cisplatin with autologous hematopoietic progenitor cell rescue. Proc Am Soc Clin Oncol 1995; 14: 477
   Web of Science ®Google Scholar
• Crown J, Raptis G, Hamilton N, Fennelly D, Vahdat L, Norton L. High-dose chemotherapy of breast cancer: current status and development strategies. Eur J Cancer 1995; 31A: 809–11
   PubMed Web of Science ®Google Scholar
• Ayash L, Elias A, Wheeler C, et al. Double dose-intensive chemotherapy with autologous marrow and peripheralblood progenitor-cell support for metastatic cancer: a feasibility study. J Clin Oncol 1994; 12: 37–44
   PubMed Web of Science ®Google Scholar
• Antman K, Ayash L, Elias A, et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992; 10: 102–10
   PubMed Web of Science ®Google Scholar